Regulatory approval

Published by the Health Products Regulatory Authority. Approved

Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.

This is written in the approval document.

Citation

Novartis Ireland Limited. Femara 2.5 mg film-coated tablets (Letrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf. Revised August 2024. Accessed May 25, 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HPRA (1) ER positive, PR positive Invasive Breast Carcinoma Letrozole
HPRA (1) ER positive Invasive Breast Carcinoma Letrozole
HPRA (1) PR positive Invasive Breast Carcinoma Letrozole